Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Obstetrics and Gynecology Reports
Erschienen in: Current Obstetrics and Gynecology Reports 4/2015

01.12.2015 | Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)

Natural History of Human Papilloma Virus Infection of the Cervix

verfasst von: Matthys Hendrik Botha

Erschienen in: Current Obstetrics and Gynecology Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Persistent HPV infection with an oncogenic strain of high-risk HPV is a necessary risk factor for the development of invasive cervical cancer. The improved understanding of the cytopathic effects of HPV led to the development of novel diagnostic and preventative tools. HPV manages to evade the immune response of the host. Oncogenic HPV infection does not progress to cancer in all infected individuals and certain variables make individuals more susceptible to the development of pre-malignant and malignant disease. The alpha HPV types are divided into high- and low-risk types according to their ability to cause malignant disease. HPV is mostly transmitted by mucosal contact and infects basal keratinocytes, most likely at a site of micro-trauma that exposes the basal layer to virus. The ability of low-risk HPV to disrupt cell proliferation is limited. In high-risk HPV infections, E6 and E7 are expressed early and strongly leading to accumulation of genetic changes that progress to cancer. The specific HPV type is the strongest factor associated with persistence and oncogenic potential. The concept of latency and reactivation may explain the re-emergence of HPV DNA detection many years after exposure. After a period of latency, reactivation of detectable HPV may follow immune suppression or hormonal changes.
Literatur
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
2.
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12–23.CrossRefPubMed
3.
Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3–13.CrossRefPubMed
4.
Woolhouse M, Scott F, Hudson Z, Howey R, Chase-Topping M. Human viruses: discovery and emergence. Philos Trans R Soc Lond B Biol Sci. 2012;367(1604):2864–71.PubMedCentralCrossRefPubMed
5.
Fornaciari G, Zavaglia K, Giusti L, Vultaggio C, Ciranni R. Human papillomavirus in a 16th century mummy. Lancet. 2003;362(9390):1160.CrossRefPubMed
6.••
Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26 Suppl 10:K1–K16. Comprehensive review of the topic.CrossRefPubMed
7.•
Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013;445(1–2):21–34. Good overview of HPV associated disease.CrossRefPubMed
8.
Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30 Suppl 5:F55–70.CrossRefPubMed
9.
Bravo IG, de Sanjose S, Gottschling M. The clinical importance of understanding the evolution of papillomaviruses. Trends Microbiol. 2010;18(10):432–8.CrossRefPubMed
10.
Quint KD, Genders RE, de Koning MN, Borgogna C, Gariglio M, Bouwes Bavinck JN, et al. Human Beta-papillomavirus infection and keratinocyte carcinomas. J Pathol. 2015;235(2):342–54.CrossRefPubMed
11.
Seedat RY, Thukane M, Jansen AC, Rossouw I, Goedhals D, Burt FJ. HPV types causing juvenile recurrent laryngeal papillomatosis in South Africa. Int J Pediatr Otorhinolaryngol. 2010;74(3):255–9.CrossRefPubMed
12.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed
13.
Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol. 2003;201(4):535–43.CrossRefPubMed
14.
Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer J Int Cancer. 1996;68(6):766–9.CrossRef
15.
World Health Oorganization International Agency For Research On Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, volume 90, human papillomaviruses. 2006.
16.
Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24 Suppl 3:S3/11–25.
17.•
Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A. 2012;109(26):10516–21. Novel concept of uniqueness of cervical transformation zone.PubMedCentralCrossRefPubMed
18.
Wang X, Ouyang H, Yamamoto Y, Kumar PA, Wei TS, Dagher R, et al. Residual embryonic cells as precursors of a Barrett’s-like metaplasia. Cell. 2011;145(7):1023–35.PubMedCentralCrossRefPubMed
19.
Yang EJ, Quick MC, Hanamornroongruang S, Lai K, Doyle LA, McKeon FD, et al. Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk. Mod Pathol : Off J U S Can Acad Pathol Inc. 2015;28(7):994–1000.CrossRef
20.
Kurman RJ, Schiffman MH, Lancaster WD, Reid R, Jenson AB, Temple GF, et al. Analysis of individual human papillomavirus types in cervical neoplasia: a possible role for type 18 in rapid progression. Am J Obstet Gynecol. 1988;159(2):293–6.CrossRefPubMed
21.
Woodman CB, Collins S, Rollason TP, Winter H, Bailey A, Yates M, et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet. 2003;361(9351):40–3.CrossRefPubMed
22.
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.CrossRefPubMed
23.
Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24 Suppl 3:S3/52–61.
24.
25.
26.
Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin genet Dev. 2002;12(1):60–6.CrossRefPubMed
27.
Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831–6.CrossRefPubMed
28.
Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodill A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J cancer J Int cancer. 2006;118(6):1481–95.CrossRef
29.
Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361(9364):1159–67.CrossRefPubMed
30.
Monnier-Benoit S, Mauny F, Riethmuller D, Guerrini JS, Capilna M, Felix S, et al. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecol Oncol. 2006;102(1):22–31.CrossRefPubMed
31.
32.
Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1808–16.CrossRefPubMed
33.
Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer J Int Cancer. 2006;119(7):1623–9.CrossRef
34.
Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1):76–84.CrossRefPubMed
35.
36.
37.
Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007;7(1):79–89.CrossRefPubMed
38.
Maglennon GA, McIntosh P, Doorbar J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology. 2011;414(2):153–63.PubMedCentralCrossRefPubMed
39.
Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol. 2000;96(3):403–9.CrossRefPubMed
40.
Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91(3):226–36.CrossRefPubMed
41.
Zeier MD, Botha MH, van der Merwe FH, Eshun-Wilson I, van Schalkwyk M, la Grange M, et al. Progression and persistence of low-grade cervical squamous intraepithelial lesions in women living with human immunodeficiency virus. J Lower Genit tract Dis. 2012;16(3):243–50.CrossRef
42.
Moodley M, Mould S. Invasive cervical cancer and human immunodeficiency virus (HIV) infection in KwaZulu-Natal, South Africa. J obstet Gynaecol : J Inst Obstet Gynaecol. 2005;25(7):706–10.CrossRef
43.
Averbach SH, Gravitt PE, Nowak RG, Celentano DD, Dunbar MS, Morrison CS, et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS. 2010;24(7):1035–42.PubMedCentralCrossRefPubMed
44.
Auvert B, Lissouba P, Cutler E, Zarca K, Puren A, Taljaard D. Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. J Acquir Immune Defic Syndr. 2010;53(1):111–6.PubMedCentralCrossRefPubMed
45.
Veldhuijzen NJ, Vyankandondera J, van de Wijgert JH. HIV acquisition is associated with prior high-risk human papillomavirus infection among high-risk women in Rwanda. AIDS. 2010;24(14):2289–92.CrossRefPubMed
46.
van der Loeff MF, Nyitray AG, Giuliano AR. HPV vaccination to prevent HIV infection: time for randomized controlled trials. Sex Transm Dis. 2011;38(7):640–3.CrossRefPubMed
47.•
Denny LA, Franceschi S, de Sanjose S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012;30 Suppl 5:F168–74. Good overview of HPV disease in immunocompromised individuals.CrossRefPubMed
Metadaten
Titel
Natural History of Human Papilloma Virus Infection of the Cervix
verfasst von
Matthys Hendrik Botha
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Current Obstetrics and Gynecology Reports / Ausgabe 4/2015
Elektronische ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-015-0135-x

Weitere Artikel der Ausgabe 4/2015

Current Obstetrics and Gynecology Reports 4/2015 Zur Ausgabe

Gynecologic Oncology (R Salani, Section Editor)

The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions

Gynecologic Oncology (R Salani, Section Editor)

Obesity Education Strategies for Cancer Prevention in Women’s Health

Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)

Human Papillomavirus (HPV) Testing for Secondary Prevention of Cervical Cancer

Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)

Epidemiology and Burden of Disease Associated with HPV Infection

Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)

Immunology of HPV Infection

Gynecologic Oncology (R Salani, Section Editor)

Nutrition in Gynecologic Cancer

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise